Australia, Feb. 20 -- Ionis Pharmaceuticals Inc., owns the trademark (2590324) for 'ZIRDAWNY' till Sept. 26, 2035.

Status: registered: Registered/protected

Classes: 5 [Pharmaceutical preparations and substances for the treatment of edema, namely, hereditary angioedema; pharmaceutical products and preparations in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders.], 44 [Medical services; medical information services; providing medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders via a website; medical consulting services in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune lymphoproliferative, and rare diseases and disorders, and collecting data and information on autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders for treatment and diagnostic purposes via an online database; providing medical and healthcare information concerning the screening, diagnosis, and treatment of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders.], 5 [Pharmaceutical preparations and substances for the treatment of edema, namely, hereditary angioedema; pharmaceutical products and preparations in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders.] and 44 [Medical services; medical information services; providing a website featuring medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; medical consulting services in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune lymphoproliferative, and rare diseases and disorders, and collecting data and information on autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders.]

Type of Mark: Word

Date of Acceptance: Dec. 12, 2025

Registration Advertised: Feb. 19

For further details contact Duncan Cotterill Lawyers.

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2590324.

Disclaimer: Curated by HT Syndication.